Prenatal Identification of Confined Placental Mosaicism in Pregnant Women with Fetal Growth Restriction

Reprod Sci. 2022 Mar;29(3):896-903. doi: 10.1007/s43032-021-00772-3. Epub 2021 Oct 28.

Abstract

We examined the influence of confined placental mosaicism (CPM) as a cause of fetal growth restriction (FGR), and whether CPM can be screened using cell-free DNA (cfDNA) analysis of the maternal plasma. We analyzed cfDNA in the maternal plasma of 40 FGR cases with an estimated fetal weight of less than - 2.0 SD using massively parallel sequencing to detect chromosomal aberrations. Fetal and placental genotyping was performed to confirm CPM cases. cfDNA analyses of maternal plasma detected suspected CPM cases with chromosomal aneuploidy or copy number variations in 5 of 40 cases (12.5%). For 4 cases in which the entire placenta consisted of cells with chromosomal abnormalities, fetal growth was severely restricted. CPM can be screened by cfDNA analysis in maternal plasma, accounting for approximately 10% of the causes of moderate or severe FGR, and the higher the proportion of abnormal karyotype cells in the placenta, the more severe the placental dysfunction and FGR.

Keywords: Cell-free DNA in maternal plasma; Confined placental mosaicism; Fetal growth restriction; Noninvasive assessment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aneuploidy
  • Cell-Free Nucleic Acids / blood*
  • DNA Copy Number Variations
  • Female
  • Fetal Growth Retardation / genetics*
  • Humans
  • Karyotyping
  • Mosaicism*
  • Placenta Diseases / genetics*
  • Pregnancy
  • Prenatal Diagnosis

Substances

  • Cell-Free Nucleic Acids